Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Achillion Pharmaceuticals received early financing of $41.0M on 2002-01-28.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $41M | 01/2002 |
| Post Ipo Equity | $50.1M | 08/2010 |
| Investors | Security type |
|---|---|
| Oakwood Medical Investors | Series Unknown |
| Ge Capital | Series Unknown |
| Pacific Growth Equities LLC | Series Unknown |
| Advent International | Series Unknown |
| Connecticut Innovations | Series Unknown |
| ING Furman Selz Asset Management | Series Unknown |
| Bear Stearns | Series Unknown |
| Schroders | Series Unknown |
| KBL Healthcare Ventures | Series Unknown |
| Atlas Venture | Series Unknown |
| Pappas Ventures | Post Ipo Equity |
| CLARUS VENTURES LLC | Post Ipo Equity |
| Quaker Bio Ventures | Post Ipo Equity |
| Domain Associates | Post Ipo Equity |
Achillion Pharmaceuticals's top competitor, Vertex Pharmaceuticals, earned an annual revenue of $11.0B.
Achillion Pharmaceuticals's smallest competitor is Chiasma with revenue of $1.1M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Chiasma | $65,048 | $1.1M | 18 | - |
| BASi | $75,192 | $23.5M | 421 | - |
| U.S. Pharmacopeia | $89,731 | $170.0M | 750 | 26 |
| Axio Research | $75,972 | $5.4M | 50 | 1 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 303 |
| Pharmaceutical Research Associates, Inc. | $77,178 | $30.0M | 30 | 7 |
| Incyte | $103,592 | $4.2B | 1,600 | 50 |
| Biocon | $73,276 | $590.0M | 9,234 | 1 |
| Pacific Biomarkers | $78,220 | $6.1M | 125 | - |
Zippia gives an in-depth look into the details of Achillion Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Achillion Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Achillion Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Achillion Pharmaceuticals. The data presented on this page does not represent the view of Achillion Pharmaceuticals and its employees or that of Zippia.
Achillion Pharmaceuticals may also be known as or be related to ACHILLION PHARMACEUTICALS INC, Achillion Pharmaceuticals, Achillion Pharmaceuticals Inc, Achillion Pharmaceuticals Inc. and Achillion Pharmaceuticals, Inc.